Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
Thursday, November 13, 2008 - 13:14
in Health & Medicine
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Read the whole article on Physorg
More from Physorg
Related
- Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patientsThu, 13 Nov 2008, 10:51:01 EST
- Advanced lung cancer patients see improved, progression-free survivalThu, 13 Nov 2008, 10:51:04 EST
- Tissue analyses indicate survival benefits for some lung cancer patientsThu, 13 Nov 2008, 10:51:06 EST
- Proton therapy may reduce serious side effect of lung cancer treatmentThu, 13 Nov 2008, 10:51:08 EST
- Vandetanib shows clinical benefit when combined with docetaxel for lung cancerMon, 1 Jun 2009, 9:44:28 EDT